Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

An improved matrix-assisted laser desorption ionization-time of flight mass spectrometry data analysis pipeline for the identification of carbapenemase-producing Klebsiella pneumoniae

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Candela, Ana
  • Galán, Fátima
  • Rodiño-Janeiro, Bruno Kotska
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Alioto, Tyler S.
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Rodríguez-Sánchez, Belén
  • Bou, Germán
  • Oviaño, Marina
[Abstract] The increasing emergence of carbapenemase-producing Klebsiella pneumoniae (CPK) isolates is a global health alarm. Rapid methods that require minimum sample preparation and rapid data analysis are urgently required. Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used by clinical laboratories for identification of antibiotic-resistant bacteria; however, discrepancies have arisen regarding biological and technical issues. The aim of this study was to standardize an operating procedure and data analysis for identification of CPK by MALDI-TOF MS. To evaluate this approach, a series of 162 K. pneumoniae isolates (112 CPK and 50 non-CPK) were processed in the MALDI BioTyper system (Bruker Daltonik, Germany) following a standard operating procedure. The study was conducted in two stages; the first is denominated the "reproducibility stage" and the second "CPK identification." The first stage was designed to evaluate the biological and technical variation associated with the entire analysis of CPK and the second stage to assess the final accuracy of MALDI-TOF MS for the identification of CPK. Therefore, we present an improved MALDI-TOF MS data analysis pipeline using neural network analysis implemented in Clover MS Data Analysis Software (Clover Biosoft, Spain) that is designed to reduce variability, guarantee interlaboratory reproducibility, and maximize the information selected from the bacterial proteome. Using the random forest (RF) algorithm, 100% of CPK isolates were correctly identified when all the peaks in the spectra were selected as input features and total ion current (TIC) normalization was applied. Thus, we have demonstrated that real-time direct tracking of CPK is possible using MALDI-TOF MS., This work was supported by funding awarded to M.O. through the Competitive Research Call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria through grants no. PI15/00860 and PI18/00860 to G.B., integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), grant no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the ISCIII, General Subdirection of Assessment and Promotion of the Research, European Regional Development Fund (FEDER) A Way of Making Europe. M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. by the research call 2019 of the SEIMC.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Occurrence of the p019 gene in the blaKPC-harboring plasmids: adverse clinical impact for direct tracking of KPC-producing Klebsiella pneumoniae by matrix-assisted laser desorption ionization-time of flight mass spectrometry

  • Gato, Eva
  • Constanso-Conde, Ignacio
  • Rodiño-Janeiro, Bruno Kotska
  • Guijarro-Sánchez, Paula
  • Alioto, Tyler S.
  • Arroyo, Manuel J.
  • Méndez, Gema
  • Mancera, Luis
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Bou, Germán
  • Oviaño, Marina
[Abstract] Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has recently been used for the direct detection of KPC-producing isolates by analysis of the 11,109 Da mass peak representing the P019 protein. In this study, we evaluate the presence of the 11,109 Da mass peak in a collection of 435 unduplicated Klebsiella pneumoniae clinical isolates. The prevalence of the P019 peak in the blaKPC K. pneumoniae isolates was 49.2% (32/65). The 11,109 Da mass peak was not observed in any of the other carbapenemase (319) or noncarbapenemase producers (116). Computational analysis of the presence of the p019 gene was performed in the aforementioned carbapenemase-producing K. pneumoniae isolates fully characterized by whole-genome sequencing (WGS) and in a further collection of 1,649 K. pneumoniae genomes included in EuSCAPE. Herein, we have demonstrated that the p019 gene is not exclusively linked to the pKpQil plasmid but that it is present in the following plasmids: IncFIB(K)/IncFII(K)/ColRNAI, IncFIB(pQil), IncFIB(pQil)/ColRNAI, IncFIB(pQil)/IncFII(K), IncFIB(K)/IncFII(K), and IncX3. In addition, we have proven the independent movement of the Tn4401 and the ISKpn31, of which the p019 gene is a component. The absence of the p019 gene was obvious in Col440I, Col(pHAD28), IncFIB(K)/IncX3/IncFII(K), and IncFIB(K)/IncFII(K) plasmids. In addition, we also observed another plasmid in which neither Tn4401 nor ISKpn31 was found, IncP6. In the EuSCAPE, the occurrence of p019 varied from 0% to 100% among the different geographical locations. The adverse clinical impact of the diminished prevalence of the p019 gene within the plasmid encoding KPC-producing Klebsiella pneumoniae puts forward the need for reconsideration when applying this technique in a clinical setting., This study was supported by funding awarded to M.O. throughout the competitive research call 2019 of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). The research was also funded by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B.) integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII) and by the Spanish Network of Research in Infectious Diseases (REIPI), number RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation2013 to 2016 and funded by the ISCIII- General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe.” M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006) and E.G. was financially supported by the research call 2019 of the SEIMC. Clover Biosoft has received funding from the European Union’s Horizon H2020 research and innovation program under grant agreement number 868365.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

  • Vázquez-Ucha, Juan Carlos
  • Seoane-Estévez, Alejandro
  • Rodiño-Janeiro, Bruno Kotska
  • González-Bardanca, Mónica
  • Conde-Pérez, Kelly
  • Martínez Guitián, Marta
  • Álvarez-Fraga, Laura
  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Gut, Marta
  • Gut, Ivo
  • Álvarez-Tejado, Miguel
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background: Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives: To assess the in vitro activity of imipenem/relebactam against a Spanish nationwide collection of CPE by testing the susceptibility of these isolates to 16 widely used antimicrobials and to determine the underlying β-lactam resistance mechanisms involved and the molecular epidemiology of carbapenemases in Spain. Materials and methods: Clinical CPE isolates (n = 401) collected for 2 months from 24 hospitals in Spain were tested. MIC50, MIC90 and susceptibility/resistance rates were interpreted in accordance with the EUCAST guidelines. β-Lactam resistance mechanisms and molecular epidemiology were characterized by WGS. Results: For all isolates, high rates of susceptibility to colistin (86.5%; MIC50/90 = 0.12/8 mg/L), imipenem/relebactam (85.8%; MIC50/90 = 0.5/4 mg/L) and ceftazidime/avibactam (83.8%, MIC50/90 = 1/≥256 mg/L) were observed. The subgroups of isolates producing OXA-48-like (n = 305, 75.1%) and KPC-like enzymes (n = 44, 10.8%) were highly susceptible to ceftazidime/avibactam (97.7%, MIC50/90 = 1/2 mg/L) and imipenem/relebactam (100.0%, MIC50/90 = ≤0.25/1 mg/L), respectively. The most widely disseminated high-risk clones of carbapenemase-producing Klebsiella pneumoniae across Spain were found to be ST11, ST147, ST392 and ST15 (mostly associated with OXA-48) and ST258/512 (in all cases producing KPC). Conclusions: Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI15/00860, PI18/00860 to G.B. and PI17/01482, PI20/01212 to A.B.) integrated in the Plan Nacional de I + D and funded by the Instituto de Salud Carlos III (ISCIII). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII—General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe’.